華納藥廠(688799.SH):擬出資不超4000萬元認繳禾怡遠景17.9767%的出資額
格隆匯5月23日丨華納藥廠(688799.SH)公佈,為藉助專業投資機構的投資經驗和資源,探索生物技術、創新藥、醫療服務、醫療器械領域及中國、東南亞等市場醫療大健康領域的投資機會,華納藥廠擬以自有資金認繳出資不超過人民幣4,000萬元,認繳禾怡遠景17.9767%的出資額。公司作為有限合夥人不參與標的基金投資及投資退出的決策,由標的基金執行事務合夥人對項目投資的立項、投資、投後管理重大事項及退出進行專業決策。
該基金投資於境內和境外醫療健康行業相關投資領域和相關行業的早中期、初創期企業,定位為醫療大健康領域早期成長階段風險投資基金,專注於生物技術、創新藥、醫療服務、醫療器械領域的創新和價值投資,旨在投資中國、東南亞等市場醫療大健康領域的創業公司,與公司主營業務具備相關性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.